| scholarly article | Q13442814 |
| editorial | Q871232 |
| P356 | DOI | 10.1200/JCO.2011.34.9266 |
| P698 | PubMed publication ID | 21555698 |
| P50 | author | George Sledge | Q92594250 |
| P2093 | author name string | Bryan P Schneider | |
| P433 | issue | 18 | |
| P304 | page(s) | 2444-2447 | |
| P577 | publication date | 2011-05-09 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners? | |
| P478 | volume | 29 |
| Q96135356 | Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment |
| Q37963955 | Benefit-risk assessment of bevacizumab in the treatment of breast cancer. |
| Q35678431 | Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. |
| Q37226530 | Leptin's Pro-Angiogenic Signature in Breast Cancer |
| Q26996793 | Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment |
| Q34079689 | Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies |
| Q30537414 | Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial |
| Q35882244 | Serpin-derived peptides are antiangiogenic and suppress breast tumor xenograft growth |
| Q39521987 | Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts |
| Q36182795 | Targeting angiogenesis in metastatic breast cancer |
| Q26779248 | The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer |
Search more.